Cellyan Biotechnology (HKPD) Total Debt (2024 - 2026)
Cellyan Biotechnology (HKPD) posted quarterly Total Debt of $2.7 million for Q3 2025, up 115.73% year-over-year from $1.2 million in Q3 2024, and down 11.25% quarter-over-quarter from $3.0 million in Q1 2025.
Cellyan Biotechnology (HKPD) Total Debt (2024 - 2026) Analysis & Trends
Cellyan Biotechnology (HKPD) has reported Total Debt for 2 consecutive years, with $2.7 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Total Debt rose 115.73% year-over-year to $2.7 million; the TTM figure through Sep 2025 stood at $2.7 million (up 115.73% YoY), while the FY2025 annual figure was $3.0 million, up 131.39% from the prior year.
- Total Debt declined to $2.7 million in Q3 2025 per HKPD's latest filing, from $3.0 million in the prior quarter.
- Across five years, Total Debt topped out at $3.0 million in Q1 2025 and bottomed at $1.2 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 102.24 Bn | 97.08 Bn | 3.69 Bn | 11.03 Bn |
| 2 | Cencora | 61.50 Bn | 58.68 Bn | 3.61 Bn | 12.00 Bn |
| 3 | Cardinal Health | 54.03 Bn | 49.18 Bn | 2.56 Bn | 8.89 Bn |
| 4 | Henry Schein | 10.04 Bn | 9.88 Bn | 1.10 Bn | 3.32 Bn |
| 5 | Akso Health | 676.38 Mn | 676.18 Mn | - | 350,527.00 |
| 6 | Edap Tms | 156.87 Mn | 135.32 Mn | 7.34 Mn | 39.06 Mn |
| 7 | Accendra Health | 91.65 Mn | 84.00 Mn | 263.41 Mn | 1.72 Bn |
| 8 | 111 | 30.17 Mn | -28.59 Mn | 18.18 Mn | 37.19 Mn |
| 9 | Cosmos Health | 13.05 Mn | 10.61 Mn | 1.51 Mn | 11.94 Mn |
| 10 | Cellyan Biotechnology | 6.61 Mn | 6.38 Mn | - | 877,904.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 877,904.00 |
| Sep 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 3.01 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Mar 31, 2024 | 1.30 Mn |